Italia markets closed

Novozymes A/S (NVZMF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
59,510,00 (0,00%)
Alla chiusura: 03:15PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente59,51
Aperto59,46
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno59,51 - 59,51
Intervallo di 52 settimane38,16 - 82,30
Volume500
Media Volume1.342
Capitalizzazione15,973B
Beta (5 anni mensile)0,39
Rapporto PE (ttm)34,40
EPS (ttm)1,73
Prossima data utiliN/D
Rendimento e dividendo (forward)0,82 (1,34%)
Data ex dividendo17 mar 2022
Stima target 1AN/D
  • GlobeNewswire

    As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative

    Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero. COPENHAGEN, Denmark – November 10, 2022. Novozymes’ first science-based targets were approved in 2019. Today Novozymes has new, SBTi approved near and long-term science-based emission reduction targets and is one of the first companies in the world to have committed to S

  • GlobeNewswire

    Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

    COPENHAGEN, Denmark – November 10, 2022. Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio’s environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical trial of probiotics sponsored by Novozymes’ human healt

  • GlobeNewswire

    Novozymes confirms upgraded guidance by strong start to Q4

    Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum. COPENHAGEN, Denmark – November 3, 2022. In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin o